Bing Xu1, Hong Tian, Shu-Yun Zhou. 1. Department of Hematology, Nanfang Hospital, The First Military Medical University, Guangzhou, Guangdong, 510515, P.R.China. xbzj@fimmu.edu.com
Abstract
BACKGROUND & OBJECTIVE: Fms-like tyrosine kinase 3 (FLT3)gene abnormal expression could be detected in most of acute myeloid leukemia (AML)patients, and 20%-30% of them have FLT3/ITD gene mutation which indicate poor prognosis. This study was to detect FLT3 gene expression, and FLT3/ITD gene mutation in chronic myeloid leukemia (CML)patients, and analyze their relationships with prognosis. METHODS: Polymerase chain reaction (PCR)was used to detect FLT3 gene expression, and FLT3/ITD gene mutation in 53 CML patients of chronic phase,and 34 CML patients of accelerated phase or blast crisis. RESULTS: FLT3 gene was detected in 5.7%(3/53)CML patients of chronic phase, and in 55.9% (19/34)CML patients of accelerated phase or blast crisis,the difference of FLT3 gene positive rate between these 2 groups was significant (P< 0.001). Only 2 of 87 CML patients (2.3%)were found with FLT3/ITD mutation. CONCLUSIONS: FTL3 gene expresses mainly in CML patients of accelerated phase or blast crisis. FTL3/ITD gene mutation was seldom involved in CML patients. The CML patients with FLT3 gene expression and FTL3/ITD gene mutation may have poor prognosis.
BACKGROUND & OBJECTIVE:Fms-like tyrosine kinase 3 (FLT3)gene abnormal expression could be detected in most of acute myeloid leukemia (AML)patients, and 20%-30% of them have FLT3/ITD gene mutation which indicate poor prognosis. This study was to detect FLT3 gene expression, and FLT3/ITD gene mutation in chronic myeloid leukemia (CML)patients, and analyze their relationships with prognosis. METHODS: Polymerase chain reaction (PCR)was used to detect FLT3 gene expression, and FLT3/ITD gene mutation in 53 CMLpatients of chronic phase,and 34 CMLpatients of accelerated phase or blast crisis. RESULTS:FLT3 gene was detected in 5.7%(3/53)CMLpatients of chronic phase, and in 55.9% (19/34)CMLpatients of accelerated phase or blast crisis,the difference of FLT3 gene positive rate between these 2 groups was significant (P< 0.001). Only 2 of 87 CMLpatients (2.3%)were found with FLT3/ITD mutation. CONCLUSIONS: FTL3 gene expresses mainly in CMLpatients of accelerated phase or blast crisis. FTL3/ITD gene mutation was seldom involved in CMLpatients. The CMLpatients with FLT3 gene expression and FTL3/ITD gene mutation may have poor prognosis.